RBP2 and hepatocellular carcinoma: Wang et al. demonstrated that RBP2 expression is an independent poor prognostic factor for DFS and OS in HCC, that it is closely related to tumor angiogenesis, and that RBP2 is a new potential therapeutic target for HCC (Wang et al. 2017).